IQVIA (NYSE:IQV) Rating Lowered to “Hold” at Wall Street Zen

IQVIA (NYSE:IQV) was downgraded by equities research analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a note issued to investors on Saturday.

IQV has been the subject of a number of other research reports. Citigroup decreased their target price on shares of IQVIA from $230.00 to $200.00 and set a “neutral” rating for the company in a research note on Friday. Robert W. Baird set a $258.00 price objective on IQVIA and gave the company an “outperform” rating in a research report on Wednesday, October 29th. Stifel Nicolaus dropped their target price on IQVIA from $273.00 to $220.00 and set a “buy” rating on the stock in a report on Friday. JPMorgan Chase & Co. cut their target price on IQVIA from $255.00 to $225.00 and set an “overweight” rating on the stock in a research note on Friday. Finally, Mizuho set a $266.00 price target on IQVIA in a research report on Friday, January 9th. Two research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $241.75.

IQVIA Trading Up 3.6%

NYSE IQV opened at $187.50 on Friday. The firm has a market capitalization of $31.93 billion, a PE ratio of 23.85, a P/E/G ratio of 1.90 and a beta of 1.37. The stock’s 50 day moving average is $228.03 and its 200 day moving average is $209.87. IQVIA has a twelve month low of $134.65 and a twelve month high of $247.04. The company has a quick ratio of 0.70, a current ratio of 0.75 and a debt-to-equity ratio of 2.09.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Thursday, February 5th. The medical research company reported $3.42 EPS for the quarter, beating the consensus estimate of $3.40 by $0.02. The business had revenue of $4.36 billion during the quarter, compared to analyst estimates of $4.24 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.34%.The company’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same quarter last year, the firm posted $3.12 earnings per share. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. Research analysts forecast that IQVIA will post 10.84 earnings per share for the current fiscal year.

Institutional Trading of IQVIA

Large investors have recently made changes to their positions in the stock. Ameliora Wealth Management Ltd. bought a new stake in IQVIA in the 4th quarter worth approximately $25,000. Physician Wealth Advisors Inc. boosted its stake in shares of IQVIA by 1,340.0% in the 3rd quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock worth $27,000 after buying an additional 134 shares during the last quarter. International Assets Investment Management LLC bought a new stake in shares of IQVIA in the fourth quarter worth $27,000. Westside Investment Management Inc. increased its position in IQVIA by 219.6% during the third quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company’s stock valued at $30,000 after acquiring an additional 101 shares during the last quarter. Finally, Measured Wealth Private Client Group LLC bought a new position in IQVIA in the third quarter valued at about $30,000. 89.62% of the stock is currently owned by institutional investors.

Trending Headlines about IQVIA

Here are the key news stories impacting IQVIA this week:

• Positive Sentiment: Q4 results beat consensus: IQV reported Q4 EPS of $3.42 and revenue of $4.36B, both above estimates and showing double‑digit Y/Y sales growth — a core reason buyers are stepping in. IQVIA Holdings (IQV) Q4 Earnings and Revenues Top Estimates
• Positive Sentiment: FY‑2026 guidance modestly raised on revenue and EPS ranges (EPS 12.55–12.85; revenue $17.2B–$17.4B) — guidance came in around or slightly above Street revenue/consensus EPS, supporting near‑term sentiment. IQVIA’s (NYSE:IQV) Q4 CY2025 Sales Top Estimates
• Positive Sentiment: Jefferies lowered its price target to $255 but kept a “buy” rating — that still implies sizable upside vs. the current price and helps underpin demand from buy‑side holders. Jefferies PT Cut (Benzinga)
• Neutral Sentiment: Citigroup trimmed its price target to $200 and moved to “neutral” — a calibration of expectations but not a full sell signal. Citigroup PT Change (Benzinga)
• Neutral Sentiment: Analyst commentary and value‑style writeups (Zacks) highlight IQV as a longer‑term value play based on style scores — useful for longer‑horizon investors rather than short‑term movers. Why IQVIA Is a Top Value Stock (Zacks)
• Negative Sentiment: IQV warned that higher interest expenses will weigh on annual profit, and Reuters notes the company forecast annual profit below Street expectations — this is increasing focus on leverage and interest‑rate sensitivity. IQV Forecasts Weak Annual Profit (Reuters)
• Negative Sentiment: Market headlines flagged that shares fell after management’s outlook for adjusted earnings missed some expectations — that knee‑jerk reaction pressured the stock before buyers re‑entered. Shares Down After Outlook Misses (MarketWatch)
• Negative Sentiment: BTIG cut its rating to neutral citing sector headwinds — another signal that some sell‑side shops are taking a more cautious near‑term stance. BTIG Cuts Rating to Neutral (MSN)

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.